bis(1-nitro-2-phenylethyl)sulfide | 52301-42-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: bis(1-nitro-2-phenylethyl)sulfide
• 英文别名: bis-(2-nitro-1-phenyl-ethyl)-sulfide；Bis-(2-nitro-1-phenyl-aethyl)-sulfid；Bis(2-nitro-1-phenylethyl) sulfide；[2-nitro-1-(2-nitro-1-phenylethyl)sulfanylethyl]benzene
• CAS: 52301-42-5
• 化学式: C₁₆H₁₆N₂O₄S
• 分子量: 332.38
• InChiKey: CMTMBVXIDSOPMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  117
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  反式硝基苯乙烯 在 1,4-二氧六环 、 二乙胺 作用下， 生成 bis(1-nitro-2-phenylethyl)sulfide
  参考文献：
  名称：

  US2511961

  摘要：

  公开号：

文献信息

• Therapeutic agents useful for treating or preventing pain
  申请人：——

  公开号：US20040006091A1

  公开（公告）日：2004-01-08

  A compound of formula: 1 (wherein X is O or S and R 1 , R 3 , R 4 , and R 5 are disclosed herein) or a pharmaceutically acceptable salt thereof (a “Thiadiazolylpiperazine Compound”), pharmaceutical compositions comprising a Thiadiazolylpiperazine Compound, and methods for treating or preventing pain in a patient comprising administering to a patient in need thereof an effective amount of a Thiadiazolylpiperazine Compound are disclosed.

  该化合物的化学式为：1（其中X为O或S，R1、R3、R4和R5在此披露）或其药用盐（“噻二唑基哌嗪化合物”），包括噻二唑基哌嗪化合物的药物组合物，以及治疗或预防患者疼痛的方法，包括向需要的患者给予有效剂量的噻二唑基哌嗪化合物。
• Method for modification of recombinant polypeptides
  申请人：BIONEBRASKA, INC.

  公开号：EP1170300A1

  公开（公告）日：2002-01-09

  The present invention provides for a method of preparing a modified recombinantly produced polypeptide including a reactive side chain group and a modified N-terminal α-amine group or C-terminal α-carboxyl group, the method comprising the steps of recombinantly forming a polypeptide having a biologically added protecting group on an N-terminal α-amine group or C-terminal α-carboxyl group, cleaving the biologically added protecting group with a cleavage reagent to form the unprotected terminal amino acid α-carbon reactive group and modifying the unprotected terminal amino acid α-carbon reactive group with a chemical modifying agent to form a terminally modified polypeptide. The invention further provides for a biologically added protecting group for a recombinantly produced polypeptide comprising a peptide or amino acid, said biologically protecting group being stable under conditions for chemical protecting reactions and including an enzymatic cleavage recognition site and a chemical cleavage recognition site, wherein the recognition sites are not present in the recombinantly produced polypeptide.

  本发明提供了一种制备修饰的重组生产的多肽的方法，该多肽包括活性侧链基团和修饰的N-末端α-氨基或C-末端α-羧基，该方法包括以下步骤 重组形成在N-末端α-氨基或C-末端α-羧基上具有生物学添加保护基团的多肽、用裂解试剂裂解生物添加的保护基团，以形成未受保护的末端氨基酸 α-碳活性基团，并用化学修饰剂修饰未受保护的末端氨基酸 α-碳活性基团，以形成末端修饰的多肽。本发明进一步提供了一种用于重组生产的多肽的生物添加保护基团，该多肽包括肽或氨基酸，所述生物保护基团在化学保护反应条件下稳定，包括酶裂解识别位点和化学裂解识别位点，其中识别位点不存在于重组生产的多肽中。
• Therapeutic agents useful for treating pain
  申请人：EURO-CELTIQUE S.A.

  公开号：EP1942106A1

  公开（公告）日：2008-07-09

  Compounds of formulae (I) and (II) where X is S or O and Ar2, R1, R2, R3, R8 n, m, and t are disclosed herein, or a pharmaceutically acceptable salt thereof (a "3-substituted Pyridyl Compound"), compositions comprising an effective amount of a 3-substituted Pyridyl Compound, and methods for treating or preventing pain, urinary incontinence, an ulcer, inflammatory-bowel disease, irritable-bowel syndrome, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a 3-substituted Pyridyl Compound are disclosed herein.

  本文公开了式(I)和(II)化合物，其中 X 为 S 或 O，Ar2、R1、R2、R3、R8 n、m 和 t 为其或其药学上可接受的盐（"3-取代吡啶基化合物"）、包含有效量 3-取代吡啶基化合物的组合物，以及治疗或预防疼痛、尿失禁、溃疡、炎症性肠病、肠易激综合征、成瘾性疾病、帕金森病、焦虑症、癫痫、帕金森病、帕金森病、帕金森病、帕金森病、帕金森病、帕金森病、帕金森病、帕金森病、帕金森病、帕金森病、帕金森病、帕金森病、帕金森病帕金森病、焦虑症、癫痫、中风、癫痫发作、瘙痒症、精神病、认知障碍、记忆缺陷、脑功能受限、亨廷顿舞蹈症、肌萎缩性脊髓侧索硬化症、痴呆症、视网膜病变、肌肉痉挛、偏头痛、呕吐、运动障碍或动物抑郁症的方法，包括向有需要的动物施用有效量的 3-取代吡啶基化合物。
• 2-Piperazine-pyridines useful for treating pain
  申请人：EURO-CELTIQUE S.A.

  公开号：EP2033951A2

  公开（公告）日：2009-03-11

  A compound of formula (I) (wherein X is O or S and R1-R5 are disclosed herein) or a pharmaceutically acceptable salt thereof (each being a "Piperazine Compound"), pharmaceutical compositions comprising a Piperazine Compound and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Piperazine Compound are disclosed.

  式（I）化合物（其中 X 为 O 或 S，R1-R5 在本文中公开）或其药学上可接受的盐（各为 "哌嗪化合物"）、包含哌嗪化合物的药物组合物以及用于治疗或预防疼痛、UI、溃疡、IBD、IBS、成瘾性疾病、帕金森病、帕金森氏症、焦虑症、癫痫、中风、瘙痒症、精神病、认知障碍、记忆缺失、脑功能受限、亨廷顿舞蹈症、肌萎缩侧索硬化症、痴呆症、视网膜病变、嗜铬细胞瘤、本发明公开了用于治疗或预防动物的疼痛、UI、溃疡、肠道疾病、肠易激综合征、成瘾性疾病、帕金森病、帕金森氏症、焦虑症、癫痫、中风、瘙痒症、精神病、认知障碍、记忆缺陷、脑功能受限、亨廷顿舞蹈症、肌萎缩侧索硬化症、痴呆症、视网膜病变、肌肉痉挛、偏头痛、呕吐、运动障碍或抑郁症的方法，包括向有需要的动物施用有效量的哌嗪化合物。
• Polymer-liquid composites for improved anti-fouling performance
  申请人：HRL Laboratories, LLC

  公开号：US11034846B2

  公开（公告）日：2021-06-15

  This disclosure describes incorporation of a liquid additive within one or more phases of a multiphase polymer coating. The structure of the microphase-separated network provides reservoirs for liquid in discrete and/or continuous phases. Some variations provide an anti-fouling segmented copolymer composition comprising: (a) one or more first soft segments selected from fluoropolymers; (b) one or more second soft segments selected from polyesters or polyethers; (c) one or more isocyanate species; (d) one or more polyol or polyamine chain extenders or crosslinkers; and (e) a liquid additive disposed in the first soft segments and/or the second soft segments. The first soft segments and the second soft segments are microphase-separated on a microphase-separation length scale from 0.1 microns to 500 microns. These solid/liquid hybrid materials improve physical properties associated with the coating in applications such as anti-fouling (e.g., anti-ice or anti-bug) surfaces, ion conduction, and corrosion resistance.

  本公开介绍了在多相聚合物涂层的一个或多个相中加入液体添加剂的方法。微相分离网络的结构为离散和/或连续相中的液体提供了储存库。一些变体提供了一种防污分段共聚物组合物，其中包括：(a) 一个或多个选自含氟聚合物的第一软段；(b) 一个或多个选自聚酯或聚醚的第二软段；(c) 一个或多个异氰酸酯品种；(d) 一个或多个多元醇或多胺扩链剂或交联剂；以及 (e) 配置在第一软段和/或第二软段中的液体添加剂。第一软段和第二软段在 0.1 微米至 500 微米的微相分离长度范围内进行微相分离。这些固/液混合材料可改善涂层在防污（如防冰或防虫）表面、离子传导和耐腐蚀性等应用中的相关物理特性。